Regular pap tests and HPV testing can prevent and often catch cases of cervical cancer. Each year, approximately 13,000 women are diagnosed with cervical cancer and about 4,000 women die from cervical cancer in the US. Sixty percent of cervical…
Today, the American Cancer Society released Cancer Statistics, 2023, the organization’s annual report on cancer facts and trends. According to the report, overall cancer mortality has dropped 33% since 1991, averting an estimated 3.8 million cancer deaths. Based on ACS data, in 2023 there are projected to be 1,958,310 new cancer cases and 609,820 cancer deaths in the United States.
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts.
Cervical cancer is often stigmatized due to its association with human papilloma virus (HPV), a sexually transmitted infection, however, HPV is extremely common, affecting most adults. Some people may also feel uncomfortable asking their doctor about sexual health .James K. Aikins, Jr., MD, FACOG, FACS, chief of Gynecologic Oncology at Rutgers Cancer Institute of New Jersey, answers questions about HPV, cervical cancer and more.
A new combination of drugs slowed the growth of cancer cells by an unexpected mechanism that may one day lead to improved treatment of cervical cancer, a UT Southwestern-led study published in Molecular Cancer Research suggests.
Analysis showed that in 2019 more than 1.3 million women received cervical cancer screening-associated services, such as a Pap test, colposcopy and other cervical procedures, after age 65. While these services cost more than $83 million, the researchers concluded they were of “unclear clinical appropriateness.”
Can mind-body practices such as gentle yoga or self-reflection benefit patients undergoing surgery? It’s a question that researchers at Wake Forest University School of Medicine are examining with the support of a five-year, $3.2 million grant from the National Cancer Institute (NCI).
A new study finds that sexual side effects of cancer treatment are discussed far less frequently with female patients than with male patients, even when the treatment directly affects sex organs.
Populations in U.S. counties defined as more vulnerable based on social factors including socioeconomic status and racial/ethnic minority status were significantly less likely to receive timely breast, cervical, and colorectal cancer screenings, according to research from UTHealth Houston.
The human papillomavirus (HPV) vaccine is safe and effective – but it’s not for everyone. Michelle Ozbun, PhD, and her team at UNM Cancer Center published a research article earlier this year in Antimicrobial Agents and Chemotherapy in which they describe how a drug called protamine sulfate blocks HPV infection. Like a game of musical chairs among molecules, the drug molecules bind to heparan sulfate cell receptors, preventing HPV virus particles from doing so.
The steepest annual rise in new cases of advanced womb (cervical) cancer in the US is among White women, who are significantly less likely to have the preventive HPV (human papillomavirus) jab or to be screened for the disease, finds research published online in the International Journal of Gynecological Cancer.
A study that surveyed cancer screening data included in medical journals worldwide from January 2020 into December 2021 showed significant decreases in the number of screenings for breast, colorectal and cervical cancers during the early phase of the Covid-19 pandemic.
New findings led by researchers at the American Cancer Society show the number of women in the United States who reported having a recent (in the past year) breast cancer or cervical cancer screening dropped by 2.13 million (6%) and 4.47 million (11%) respectively in 2020 compared to 2018. The study is the first of its kind to evaluate the impact of the COVID-19 pandemic on cancer screenings nationally using population-based data.
A recent database analysis reveals that in recent years, sexual minority individuals—those whose sexual orientation differs from societal norms—were less likely to have undergone cervical cancer screening tests than heterosexual counterparts, with Hispanic sexual minority individuals having the lowest screening rates.
The presence of Cervical Cancer Stem Cells (CCSCs) in cases of Cervical Cancer (CC) represent a small subpopulation of tumor cells with a high potential for resistance to conventional treatments.
Minimally invasive surgery was associated with lower survival rates than open surgery as a treatment for cervical cancer, according to the final analysis of data from the LACC trial.
International collaboration involving NCCN and Polish oncology officials publishes first of several evidence-based expert consensus guidelines with latest cancer treatment recommendations, adapted for regional needs, beginning with cervical cancer.
September is Gynecologic Cancer Awareness Month. Rutgers Cancer institute of New Jersey Gynecologic Oncology Chief Dr. James Aikins reminds women about the types of gynecologic cancers and their warning signs
The College of American Pathologists (CAP) Foundation announced in July 2021 a new fundraising campaign with a minimum goal of $2 million that will secure life-saving cancer screening and pathology education and training programs for the next decade.
Last year, the American Cancer Society (ACS) issued an updated set of guidelines for cervical cancer screening – emphasizing the shift toward screening with primary human papillomavirus (HPV) testing. While the ACS recommendation accounts for a transition period to implement primary HPV screening, additional factors should be considered to operationalize these guidelines, according to a special white paper in the July issue of the Journal of Lower Genital Tract Disease (JLGTD), official journal of ASCCP. The journal is published in the Lippincott portfolio by Wolters Kluwer.
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current advances include expanded use of a targeted therapy for a new group of patients with leukemia, molecular studies yielding novel cancer therapeutic targets, insights into radiation therapy resistance and a community intervention to reduce cervical cancer rates.
Sanford Burnham Prebys has joined doctors & scientists across America at National Cancer Institute (NCI)-designated cancer centers & other organizations to issue a joint statement urging the nation’s physicians, parents & young adults to get the human papillomavirus (HPV) vaccination back on track.
In a Correspondence to the New England Journal of Medicine, researchers found that many medical centers changed surgical practices for early cervical cancer based on findings from the LACC study in 2018, but non-academic medical centers could improve in making the change compared with academic centers.
Emerging technologies can screen for cervical cancer better than Pap smears and, if widely used, could save lives in areas where access to health care may be limited. In Biophysics Reviews, scientists at Massachusetts General Hospital write advances in nanotechnology and computer learning are among the technologies helping develop HPV screening that take the guesswork out of the precancer tests. That could mean better screening in places that lack highly trained doctors and advanced laboratories.
Cervical cancer is a serious global health threat which kills more than 300,000 women every year. Recognizing this urgent public health issue, the editorial team of Preventive Medicine is publishing a special issue titled “From Science to Action to Impact: Eliminating Cervical Cancer,” which outlines the required courses of action to eliminate cervical cancer. Dr. Anna Giuliano and Dr. Linda Niccolai, two giants in the field of cervical cancer prevention research, served as guest editors for the issue.
Michelle Ozbun, PhD, and her team developed a way to measure how many infectious human papillomavirus particles are left on a surface after it has been disinfected. They found that disinfectants approved for use on medical devices work well, and they recently published their work online in The Lancet journal EBioMedicine.
Cancer cases in adolescents and young adults have risen by 30% during the last four decades, with kidney cancer rising at the greatest rate, according to researchers at Penn State College of Medicine.
A phase III trial from India shows that an advanced radiation therapy technique leads to fewer gastrointestinal side effects in women who receive radiation after undergoing hysterectomy for cervical cancer. Findings from the PARCER trial (NCT01279135) will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.
During the COVID-19 pandemic, Johns Hopkins Medicine Media Relations is focused on disseminating current, accurate and useful information to the public via the media. As part of that effort, we are distributing our “COVID-19 Tip Sheet: Story Ideas from Johns Hopkins” every other Tuesday.
The best defense against gynecologic cancer starts with preventative measures. When cancer is detected early, there is a better chance of having more effective treatment and better outcomes. While there is not a single screening test for all gynecologic cancers, learn about the ones that do exist.
Human papillomavirus (HPV) is the most common sexually transmitted infection and the cause of most cervical cancers, and some vaginal, penile, anal and oral cancers. The HPV vaccine has proven effective in preventing infection and six types of HPV-attributable cancers. …
Women receiving standard treatment in New York City for ovarian, uterine, and cervical cancers are not at increased risk of being hospitalized for or dying from COVID-19 due to their cancer, a new study shows.
While the latest findings on long-term efficacy of the HPV vaccine are cause for celebration, vaccinations should be coupled with preventive screening to better protect women from cervical cancer, two University of Michigan experts argue in an invited commentary in The Lancet’s EClinicalMedicine journal.
Replacing guidelines for managing women with abnormal results on cervical cancer screening test from 2012, new recommendations from ASCCP emphasize more precise management based on estimates of the patient’s risk – enabling more personalized recommendations for diagnosis, treatment, and follow-up. The revised guidelines with updated recommendations are now available in the Journal of Lower Genital Tract Disease (JLGTD), official journal of ASCCP. The journal is published in the Lippincott portfolio by Wolters Kluwer.
A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides recommendations for radiation therapy to treat patients with nonmetastatic cervical cancer. The guideline outlines indications and best practices for EBRT and brachytherapy in postoperative and definitive settings, and it also addresses chemotherapy and surgery when used in combination with radiation. The guideline is published online in Practical Radiation Oncology.
Researchers developed a method using fluorescence to detect precancerous metabolic and physical changes in individual epithelial cells lining the cervix. The method, which can detect precancerous lesions non-invasively and non-destructively, opens the door to early-stage bedside diagnostics.
Cervical cancer is the third most common cancer in women worldwide, but most American women can prevent it by being screened on time with tests that detect human papillomaviruses (HPV). A new study led UNM Comprehensive Cancer Center scientists shows that screening every three years instead of annually prevents most cervical cancers.
The HPV vaccine protects against some of the deadliest, most disfiguring and hard-to-treat cancers. Here is what parents of teens and pre-teens should know about the HPV vaccine.
Daron G. Ferris, MD, the Founder of CerviCusco, will receive the 2020 Penn Nursing Renfield Foundation Award for Global Women’s Health for his dedication to cervical cancer prevention among the indigenous women in Cusco, Peru. Ferris created CerviCusco, a non-profit organization that ensures all women, including those with limited economic resources, have access to high quality and affordable health education and care, including screening, diagnosis, and treatment of cervical cancer. Ferris will receive the award – which comes with a $100,000 cash prize – during an event at the University of Pennsylvania on April 23, 2020.
A vaccine is available to protect against human papillomavirus (HPV). HPV is the most common sexually transmitted infection and can cause diseases such as genital warts and cancer.
The HPV vaccine now protects against nine strains of HPV. Research shows that the HPV vaccine is safe and effective.
The HPV vaccine is approved for men and women between the ages of 9 to 45. The HPV vaccine can protect adults from HPV-related diseases, however it provides the most protection when it is given in childhood before someone becomes sexually active.
Parents should talk with their child’s pediatrician about the HPV vaccine. Adult men should ask their primary care provider about the HPV vaccine, and adult women should speak with their gynecologist.
Dr. Teresa Diaz-Montes is a gynecologic surgeon who provides expertise in gynecologic cancers as well as minimally invasive surgical techniques. Teresa P. Diaz-Montes, M.D., MPH, FACOG, serves as the Associate Director of The Lya Segall Ovarian Cancer Institute. She also is a…
January is Cervical Cancer Awareness Month. A Rutgers Cancer Institute of New Jersey expert shares insight on prevention and early detection of this disease.
Rates of new anal cancer diagnoses and deaths related to human papillomavirus (HPV), the most common sexually transmitted infection, have increased dramatically over the last 15 years, according to researchers at The University of Texas Health Science Center at Houston (UTHealth). The results of their study will be published in the November issue of the Journal of the National Cancer Institute.